Heart Surgery - Heart Failure Stem Cell Therapy

Keeping in tradition with the U’s commitment to advance the fields of medicine and surgery, our physicians are focusing on regenerative medicine as the next frontier in treating cardiovascular disease.

Researchers within the Cardiovascular Center estimate cell therapy will be FDA-approved within three years. The goal of this therapy is to give cells back to the heart in order for it to grow stronger, work harder, and function more like a younger heart. Currently, studies at the U include the potentiality of injecting cardiac repair cells into patients’ hearts to improve function.

This is the first trial of its kind in the United States, providing heart patients who have limited or no other options with a viable treatment. Using some of the best imaging technology, researchers have been able to see improvements in patients within six months after injecting their own cells directly into the left ventricle of the heart during minimally invasive surgery.

Contact Us:

Phone: (801) 581-5311

Amit N. Patel, M.D., B.S., M.S.

Locations

University Hospital

(801) 587-7946

Specialties: Cardiothoracic Surgery, Heart Failure, Heart Stem Cell Therapy, Heart Transplant, Lung Transplant, Valvular Heart Disease

Craig H. Selzman, M.D.

Locations

University Hospital

(801) 587-9348

Specialties: Cardiothoracic Surgery, Adult Congenital Heart Disease, Cardiac Mechanical Support, Coronary Revascularization, Heart Failure, Heart Stem Cell Therapy, Heart Transplant, Lung Transplant, Minimally Invasive Heart Surgery, Surgical Ventricular Restoration, Valvular Heart Disease

Clinical Trials

• A Randomized Trial of Sirolimus-Based Graft versus Host Disease Prophylaxis after Hematopoietic Stem Cell Transplantation in Relapsed ALL
• Rapamyucin for Immunosuppression and B cell Modulation post stem cell transplant for acute lymphoblastic leukemia
• Assessment of the Correlation between Pre-transplant Comorbidities and Post-Transplant Outcomes Using the Hematopoietic cell Transplantation-Specific Comorbidity Index (HCT-CI): A Multi-Center Trial
• Study to determine the most promising postgrafting immunosuppression for prevention of acute GVHD after unrelated donor G-CSF mobilized peripheral blood monuclear stem cell transplantation
• Nonmyeloablative Allogeneic Peripheral Blood Stem Cell Transplantation from HLA Matched Related Donors for Treatment of Older Patients with De Novo or Secondary Acute Myeloid Leukemia in First Complete Remission
• National Marrow Donor Program (NMDP) Research Sample Depository for Unrelated Stem Cell Transplantation Research
• Study of Fludarabine Based Conditioning for Allogeneic Stem Cell Transplantation for Myelofibrosis
• Development of a National Marrow Donor Program (NMDP) Research Database for Unrelated Stem Cell Transplantion
• Compassionate Use Protocol for the use of AMD3100 to Mobilize Peripheral Blood Stem Cells for Collection and Transplantation

Related Documents

Pediatric Diseases and Conditions

• Bone Marrow Transplantation in Children

Articles

• Making the Decision to Have a Stem Cell Transplant for CLL
• What to Expect After a Stem Cell Transplant for CLL
• Making the Decision to Have a Stem Cell Transplant for Acute Lymphocytic Leukemia (ALL)
• Making the Decision to Have a Stem Cell Transplant for CML
• Targeted Therapies Take Aim at Cancer
• What Happens During a Stem Cell Transplant for Acute Lymphocytic Leukemia (ALL)
• What Happens During a Stem Cell Transplant for CML
• What to Expect After a Stem Cell Transplant for Acute Myeloid Leukemia (AML)

News

• Mouse Study Could Give New Clues to Fighting Baldness
• Specialized Adult Stem Cells Re-Grow Fingertips

Drug Reference

• Fludarabine